Комплексные проблемы сердечно-сосудистых заболеваний

Расширенный поиск


Полный текст:


Ischaemia/reperfusion cardiac injury contributes to morbidity and mortality during percutaneous coronary intervention, heart surgery and transplantation. Even when the recanalization of an infarct-related coronary artery is carried out successfully, there is still a risk of death due to reperfusion injury. Numerous pharmacological interventions have been found in experiments on animals. However, the translation of these interventions to clinical practice has been disappointing. None of the drug treatment has been able to improve in-hospital mortality of patients with acute myocardial infarction. The search for pharmacological agents able to salvage myocardium during reperfusion continues. Opioid receptor (OR) agonists represent one of the promising group of drugs for treatment of patients with myocardial infarction. It has been found that µ-, δ- and κ-OR agonists are able to attenuate heart injury when administered before or at the beginning of reperfusion. However, what kind of OR receptors need to be activated in order to protect the heart during reperfusion and the precise mechanism of this effect have yet to be elucidated.

Об авторах

I. G. Khaliulin
School of Clinical Sciences, University of Bristol
7 Bristol Royal Infirmary, Upper Maudlin Street, Bristol, BS2 8HW

L. N. Maslov
Cardiology Research Institute, Tomsk National Research Medical Centre

Список литературы

1. P.W. Serruys, M.-C. Morice , A.P. Kappetein, A. Colombo, D.R. Holmes, M.J. Mack et al. Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease. N Engl J Med. 2009; 360(10): 961-972.

2. D. Joyal, J. Afilalo, S. Rinfret Effectiveness of recanalization of chronic total occlusions: A systematic review and meta-analysis. Am Heart J. 2010; 160(1): 179-187.

3. Ito H., Okamura A., Iwakura K., Masuyama T., Hori M., Takiuchi S. et al. Myocardial Perfusion Patterns Related to Thrombolysis in Myocardial Infarction Perfusion Grades After Coronary Angioplasty in Patients With Acute Anterior Wall Myocardial Infarction. Circulation. 1996; 93(11): 1993-9.

4. S.S. Rathore, J.P. Curtis, J. Chen, Y. Wang, B.K. Nallamothu, A.J. Epstein, H.M. Krumholz R. for the National Cardiovascular Data, Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort study. BMJ. 2009; 338: b1807.

5. T. Husebye, J. Eritsland, C. Müller, L. Sandvik, H. Arnesen, I. Seljeflot, A. Mangschau, R. Bjørnerheim, G.Ø. Andersen, Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. Eur J Heart Fail. 2013; 15(5): 565-572.

6. T. Toda, T. Kadono, M. Hoshiai, Y. Eguchi, S. Nakazawa, H. Nakazawa, N. Higashijima, H. Ishida Na+/H+ exchanger inhibitor cariporide attenuates the mitochondrial Ca2+ overload and PTP opening. Am J Physiol Heart Circ Physiol. 2007; 293(6): H3517.

7. Zeymer U., Suryapranata H., Monassier J.P., Opolski G., Davies J., Rasmanis G. et al. The Na+/H+exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction1: Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol. 2001; 38(6): E1644-E1650.

8. R.M. Mentzer, Jr. C. Bartels, R. Bolli, S. Boyce, G.D. Buckberg, B. Chaitman et al. SodiumHydrogen Exchange Inhibition by Cariporide to Reduce the Risk of Ischemic Cardiac Events in Patients Undergoing Coronary Artery Bypass Grafting: Results of the EXPEDITION Study. Ann Thorac Surg. 2008; 85(4): 1261-1270.

9. L.F. González Arbeláez, A. Ciocci Pardo, J.C. Fantinelli, S.M. Mosca, Cyclosporine-A mimicked the ischemic pre- and postconditioning-mediated cardioprotection in hypertensive rats: Role of PKCε. Exp Mol Pathol. 2016; 100(2): 266-275.

10. N. Wu, W.N. Li, W.Q. Shu, Y. Lv, D.L. Jia Blocking the mitochondrial permeability transition pore with cyclosporine-A can restore cardioprotection of ischemic postconditioning in hypercholesterolemic rat heart. Eur Rev Med Pharmacol Sci. 2015; 19(3): 446-54.

11. E.J. Griffiths, A.P. Halestrap Protection by Cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol. 1993; 25(12): 1461-9.

12. T.-T. Cung, O. Morel, G. Cayla, G. Rioufol, D. Garcia-Dorado, D. Angoulvant et al. Cyclosporine before PCI in Patients with Acute Myocardial Infarction. New Eng J Med. 2015; 373(11):1021-1031. DOI: 10.1056/NEJMoa1505489

13. Roubille F., Lairez O., Mewton N., Rioufol G., Ranc S., Sanchez I. et al. Cardioprotection by clopidogrel in acute ST-elevated myocardial infarction patients: a retrospective analysis. Basic Res Cardiol. 2012; 107(4): 275. doi: 10.1007/s00395-012-0275-3. Epub 2012 Jun 21.

14. Song Y.B., Hahn J.Y., Gwon H.C., Chang S.A., Lee S.C., Choe Y.H. et al. A high loading dose of clopidogrel reduces myocardial infarct size in patients undergoing primary percutaneous coronary intervention: A magnetic resonance imaging study. Am Heart J. 2012 Mar;163(3):500-7. doi: 10.1016/j.ahj.2011.12.007.

15. Bellemain-Appaix A., O’Connor S.A., Silvain J., et al. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis. JAMA. 2012; 308(23): 2507-2516.

16. Hahn J.Y., Kim H.J., Choi Y.J., Jo S.H., Kim H.J., Lee S. et al. Effects of atorvastatin pretreatment on infarct size in patients with STsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention.Am Heart J. 2011; 162(6): 1026-33. doi: 10.1016/j.ahj.2011.08.011

17. Kim E.K., Hahn J.-Y., Song Y.B., Chang S.-A., Choi J.-H., Choi S.-H. et al. Effects of High-dose Atorvastatin Pretreatment in Patients with ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Cardiac Magnetic Resonance Study. J Korean Med Sci. 2015; 30(4): 435-441. doi: 10.3346/jkms.2015.30.4.435

18. PostS. , Post M.C., van den Branden B.J., Eefting F.D., Goumans M.-J., Stella P.R. et al. Early statin treatment prior to primary PCI for acute myocardial infarction: REPERATOR, a randomized placebo-controlled pilot trial. Catheter Cardiovasc Interv. 2012; 80(5): 756-765.

19. Mahaffey K.W., Puma J.A., Barbagelata N.A., DiCarli M.F., Leesar M.A., Browne K.F. et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) Trial. J Am Coll Cardiol. 1999; 34(6): 1711-1720.

20. Micari A., Belcik T.A., Balcells E.A., Powers E., Wei K., Kaul S., Lindner J.R. Improvement in microvascular reflow and reduction of infarct size with adenosine in patients undergoing primary coronary stenting. Am J Cardiol. 2005; 96(10):1410-1415.

21. A.M. Ross, R.J. Gibbons, G.W. Stone, R.A. Kloner, R.W. Alexander A Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial of Adenosine as an Adjunct to Reperfusion in the Treatment of Acute Myocardial Infarction (AMISTAD-II). J Am Coll Cardiol. 2005; 45(11): 1775-1780. doi:

22. Wang J., Chen Y.-D., Zhi,G. XuY., Chen,L., Liu H.-B. et al. Beneficial effect of adenosine on myocardial perfusion in patients treated with primary percutaneous coronary intervention for acute myocardial infarction.Clin Exp Pharmacol Physiol. 2012; 39(3): 247-252.

23. Cohen M.V., Downey J.M. AMISTAD Trials: Possible Reasons for Lack of Success. Journal of the American College of Cardiology. 2006; 47(6): 1236.

24. Di Pasquale P., Lo Verso P., Bucca V., Cannizzaro S., Scalzo S., Maringhini G. et al. Effects of Trimetazidine Administration before Thrombolysis in Patients with Anterior Myocardial Infarction: Short-term and Long-term Results. Cardiovasc Drugs Ther. 1999; 13(5): 423-428.

25. Steg P.G., Grollier G., Gallay P., Morice M.- C., Karrillon G.J., Benamer H. et al. A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction. Int J Cardiol. 2001; 77(2–3): 263-273.

26. Zhao Z.-Q., Corvera J.S., Halkos M.E., Kerendi F., Wang N.-P., Guyton R.A., VintenJohansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003; 285(2): H579.

27. Gong Z.X., Ran K., Chang Y.T., Xu J.M. Effect of morphine postconditioning on myocardial ischemia-reperfusion injury in rabbits. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2009; 38(5): 521-4.

28. Zhang W.P., Zong Q.F., Gao Q., Yu Y., Gu X.Y., Wang Y., Li Z.H., Ge M. Effects of endomorphin-1 postconditioning on myocardial ischemia/reperfusion injury and myocardial cell apoptosis in a rat model. Mol Med Rep. 2016; 14(4): 3992-8.

29. Gross E.R., Hsu A.K., Gross G.J. OpioidInduced Cardioprotection Occurs via Glycogen Synthase Kinase β Inhibition During Reperfusion in Intact Rat Hearts. Circ Res. 2004; 94(7): 960.

30. Maslov L.N., Khaliulin I., Zhang Y., Krylatov A.V., Naryzhnaya N.V., Mechoulam R. et al. Prospects for creation of cardioprotective drugs based on cannabinoid receptor agonists. J Cardiovasc Pharmacol Ther. 2016; 21(3): 262-272.

31. Dhawan B.N., Cesselin F., Raghubir R., Reisine T., Bradley P.B., Portoghese P.S., Hamon M. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev. 1996; 48(4): 567.

32. Peart J.N., Gross G.J. Cardioprotective effects of acute and chronic opioid treatment are mediated via different signaling pathways. Am J Physiol Heart Circ Physiol. 2006; 291(4): H1746.

33. Maslov L.N., Khaliulin I., Oeltgen P.R., Naryzhnaya N.V., Pei J.M., Brown S.A. et al. Prospects for creation of cardioprotective and antiarrhythmic drugs based on opioid receptor agonists. Med Res Rev. 2016; 36(5): 871-923.

34. Fryer R.M., Patel H.H., Hsu A.K., Gross G.J. Stress-activated protein kinase phosphorylation during cardioprotection in the ischemic myocardium. Am J Physiol Heart Circ Physiol. 2001; 281(3): H1184.

35. Xu J., Tian,W. Ma X., Guo J., Shi Q., Jin Y. et al. The Molecular Mechanism Underlying Morphine-Induced Akt Activation: Roles of protein phosphatases and reactive oxygen species. Cell Biochem Biophys. 2011; 61(2): 303-311.

36. Gross E.R., Hsu A.K., Gross G.J. The JAK/ STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3β. Am J Physiol Heart Circ Physiol. 2006; 291(2): H827.

37. Cohen M.V., Downey J.M. Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future. Br J Pharmacol. 2015; 172(8): 1913-1932.

38. Wu X., Zhang B., Fan R., Zhao L., Wang Y., Zhang S. et al. U50,488H inhibits neutrophil accumulation and TNF-α induction induced by ischemia–reperfusion in rat heart. Cytokine. 2011; 56(2): 503-507.

39. Peart J.N., Gross G.J. Adenosine and opioid receptor-mediated cardioprotection in the rat: evidence for cross-talk between receptors. Am J Physiol Heart Circ Physiol. 2003; 285(1): H81.

40. Halestrap, Clarke A.P. S.J., Khaliulin I. The role of mitochondria in protection of the heart by preconditioning. Biochim Biophys Acta. 2007; 1767(8): 1007-1031.

Для цитирования:

Khaliulin I.G., Maslov L.N. PROBLEM OF HEART SALVATION DURING REPERFUSION. OPIOID RECEPTOR AGONISTS AS A POSSIBLE SOLUTION. Комплексные проблемы сердечно-сосудистых заболеваний. 2017;(3):150-154.

For citation:

Khaliulin I., Maslov L.N. PROBLEM OF HEART SALVATION DURING REPERFUSION. OPIOID RECEPTOR AGONISTS AS A POSSIBLE SOLUTION. Complex Issues of Cardiovascular Diseases. 2017;(3):150-154.

Просмотров: 79

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 2306-1278 (Print)
ISSN 2587-9537 (Online)